Segment - Schedule of Performance Measured Used by CODM (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Operating expenses: | ||||||
| Sales and marketing | $ 1,458,470 | $ 857,847 | $ 1,740,373 | $ 2,018,422 | ||
| Research and development: | 4,553,021 | 101,278 | 4,579,321 | 190,026 | ||
| General and administrative | 3,877,442 | 670,950 | 6,032,282 | 2,167,152 | ||
| Total operating expenses | 9,888,933 | 1,630,075 | 12,351,976 | 4,375,600 | ||
| Other expense | 183,387 | 51,910 | 205,939 | 73,842 | ||
| Loss from discontinued operations | 944,160 | 1,797,848 | 3,540,547 | 4,033,282 | ||
| Net loss | (11,016,480) | $ (5,081,982) | (3,479,833) | $ (5,002,891) | (16,098,462) | (8,482,724) |
| Quantum Drones [Member] | ||||||
| Operating expenses: | ||||||
| Sales and marketing | ||||||
| Research and development: | 4,365,232 | 4,365,232 | ||||
| General and administrative | 131,455 | 131,455 | ||||
| Total operating expenses | 4,496,687 | 4,496,687 | ||||
| Other expense | ||||||
| Loss from discontinued operations | ||||||
| Net loss | (4,496,687) | (4,496,687) | ||||
| Genetic Diagnostic [Member] | ||||||
| Operating expenses: | ||||||
| Sales and marketing | 1,458,470 | 857,847 | 1,740,373 | 2,018,422 | ||
| Research and development: | 187,789 | 101,278 | 214,089 | 190,026 | ||
| General and administrative | 3,745,987 | 670,950 | 5,900,827 | 2,167,152 | ||
| Total operating expenses | 5,392,246 | 1,630,075 | 7,855,289 | 4,375,600 | ||
| Other expense | 183,387 | 51,910 | 205,939 | 73,842 | ||
| Loss from discontinued operations | 944,160 | 1,797,848 | 3,540,547 | 4,033,282 | ||
| Net loss | $ (6,519,793) | $ (3,479,833) | $ (11,601,775) | $ (8,482,724) | ||
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|